Dušan Ružić, PhD

Dr sc Dragomir Marisavljevic

Position: Assistant with PhD
Organizational unit:  Department of Pharmaceutical Chemistry
Room: 207 (Building B)
Phone:  +381 11 3951-259
E-mail: dusan.ruzic@pharmacy.bg.ac.rs

CV


Dusan Ruzic was born on June 29, 1990, in Čačak. He graduated from the Faculty of Pharmacy, University in Belgrade in 2014 with grade point average (GPA) 9.82 out of 10.0. He defended his graduate thesis at the Department of Organic Chemistry, Faculty of Pharmacy in Belgrade (Prof. Vladimir Savić, PhD, supervisor) and obtained the title of Master of Pharmacy. He was awarded the annual award "Professor Dr Ivan Berkeš" for the best pharmacy student (generation 2009-2014).

In June 2022 he defended PhD thesis entitled "Ratonal drug design, synthesis and in vitro evaluation of selective histone deacetylase 6 inhibitors" supervised by Prof. Dr Katarina Nikolic, University of Belgrade -Faculty of Pharmacy. Since March 2015, he was employed as a Graduate Researcher, then as a Research Associate on the project of the Ministry of Education, Science and Technological Development of the Republic of Serbia. From December 2019 he has been employed as a Teaching Assistant at the Department of Pharmaceutical Chemistry.

Dušan Ružić participated as an Associate Researcher at the international COST action, EpiChemBio (CM1406). As a part of the COST EpiChemBio action, he did doctoral training from 2016-2018 in the Laboratory of Chemical Biology, School of Pharmacy, University of East Anglia, Norwich, United Kingdom (Prof. A. Ganesan, PhD, supervisor). In November 2018, he was awarded by EpiChemBio COST Action to do research training in the laboratory for high-throughput screening and assay development at the Fraunhofer IME ScreeningPort, Hamburg, Germany. Dušan Ružić is interested in medicinal chemistry, organic synthesis and chemical biology of epigenetic modulators. He is member of the Cancer Epigenetic Society, the Serbian Association for Cancer Research and the American Association for Cancer Research.

  • Ruzic, D., Ellinger, B., Djokovic, N., Santibanez, J. F., Gul, S., Beljkas, M., Djuric, A., Ganesan, A., Pavic, A., Srdic-Rajic, T., Petkovic, M., & Nikolic, K. (2022). Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation. Pharmaceutics, 14(12), 2600
  • Bulut I., Lee A., Cevatemre B., Ruzic D., Belle R., Kawamura A., Gul S., Nikolic K., Ganesan A., Acilan C. (2022). Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells. Cancers, 14(23), 6014.
  • Ruzic, D., Djoković, N., Srdić-Rajić, T., Echeverria, C., Nikolic, K., & Santibanez, J. F. (2022). Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics, 14(1), 209.
  • Djokovic, N., Ruzic, D., Rahnasto-Rilla, M., Srdic-Rajic, T., Lahtela-Kakkonen, M., & Nikolic, K. (2022). Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics. Journal of Chemical Information and Modeling, 62(10), 2571-2585.
  • Bon, C., Barbachowska, M., Djokovic, N., Ruzic, D., Si, Y., Soresinetti, L., Jallet C., Tafit A., Halby L., Nikolic K., & Arimondo, P. B. (2022). Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies. Future Medicinal Chemistry, 14(8), 557-570.
  • Albert, L., Nagpal, J., Steinchen, W., Zhang, L., Werel, L., Djokovic, N., Ruzic, D., Hoffarth, M., Xu, J., Kaspareit, J., Abendroth, F., Royant, A., Bange, G., Nikolic, K., Ryu, S., Dou, Y., Essen, L.-O., & Vázquez, O. (2021). Bistable Photoswitch allows in vivo control of hematopoiesis. ACS Central Science, 8(1), 57–66.
  • Djokovic, N.#, Ruzic, D.#, Djikic, T., Cvijic, S., Ignjatovic, J., Ibric, S., Baralic, K., Buha Djordjevic, A., Curcic, M., Djukic-Cosic, D., & Nikolic, K. (2021). An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease. Molecular Informatics, 40(5), 2000187.
  • Alves Avelar, L. A., Ruzic, D., Djokovic, N., Kurz, T., & Nikolic, K. (2020). Structure-based design of selective histone deacetylase 6 zinc binding groups. Journal of Biomolecular Structure and Dynamics, 38(11), 3166-3177.
  • Bouchet, S., Linot, C., Ruzic, D., Agbaba, D., Fouchaq, B., Roche, J., Nikolic, K., Blanquart, C. and Bertrand, P., 2019. Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. ACS Medicinal Chemistry Letters, 10(6), pp.863-868.
  • Ruzic, D., Petkovic, M., Agbaba, D., Ganesan, A., & Nikolic, K. (2019). Combined Ligand and Fragment‐based Drug Design of Selective Histone Deacetylase–6 Inhibitors. Molecular informatics, 38(5), 1800083.